Rituximab combined with autologous hematopoietic stem cell transplantation for therapy of CD_(20),positive B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2009.12.023
- VernacularTitle:自体造血干细胞移植联合利妥昔单抗治疗CD_(20)~+ B细胞淋巴瘤
- Author:
Lei ZHANG
;
Weiping ZHANG
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cells;
Transplantation;
autologous;
Antibodies;
monoclonal;
Lymphoma;
B-cell
- From:
Journal of Leukemia & Lymphoma
2009;18(12):766-768
- CountryChina
- Language:Chinese
-
Abstract:
Autologous hematopoietic stem cell transplantation(AHSCT) has a good curative effect for high-risk or middle-risk aggressive lymphoma,but some patients who receive AHSCT still died of recurrence.The main reason for this is the presence of minimal residual disease (MRD), including residual tumor cells in vivo and contamination of grafts with tumor cells.Rituximab can be targeted to remove CD_(20) positive B cells,so application of rituximab before and after AHSCT may play a role in removal of residual disease and in vivo purging.Bituximab combined with AHSCT may further enhance the curative effect for CD_(20) positive B cell lymphoma.
